Skip to main content
SpringerLink
Log in

Primary and Secondary Hypogonadism in Women

  • Chapter
Hormone Replacement Therapy

Part of the book series: Contemporary Endocrinology ((COE,volume 13))

  • 149 Accesses

Abstract

Hormone replacement of hypogonadal women is a highly effective preventive health care measure. Estrogen replacement results in a nearly a 50% reduction in the risks of cardiovascular disease, vertebral and hip fractures, and Alzheimer’ s disease. Hypogonadal symptomatology such as hot flushes, irritability, anxiety, mood disturbances, loss of libido and genitourinary atrophy are reduced and often alleviated by estrogen replacement. Numerous estrogen formulations and delivery systems are available and reviewed. Progestogens are utilized in women with a uterus to reduce the risk of endometrial hyperplasia and endometrial cancer. Available progestogen formulations are discussed. The role of androgens, phytoestrogens, and DHEA in hormone replacement therapy (HRT) are noted. Risks and complications of HRT are outlined, including the potential risk of breast cancer, reduced cardiovascular benefits after long-term use, and nuisance side effects. The future role of selective estrogen receptor modulators (SERM’s) is highlighted.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hagstad A, Janson PO. The epidemiology of climacteric symptoms. Acta Obstet Gynecol Scand 1986; 134: 59–65.

    Article  CAS  Google Scholar 

  2. Witteman JCM, Brobbee DE, Kok FJ, Hofman A, Valkenburg HA. Increased risk of atherosclerosis in women after the menopause. Br Med J 1989; 298: 642–644.

    Article  CAS  Google Scholar 

  3. Colditz GA, Wilett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the riskof coronary heart disease in women. N Engl J Med 1987; 316: 1105–1110.

    Article  PubMed  CAS  Google Scholar 

  4. Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE. Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol 1981; 139: 47–51.

    PubMed  CAS  Google Scholar 

  5. Beard CM, Fuster V, Annegers FJ. Reproductive history in women with coronary heart disease: a case-control study. Am J Epidemiol 1981; 120: 108–114.

    Google Scholar 

  6. Bush, TL. Noncontraceptive estrogen use and risk of cardiovascular disease: an overview and critique of the literature. In: Kerenman, SG, eds. The menopause: Biological and Clinical Consequences of Ovarian Failure; Evolution and Management. Serono Symposia, Norwell, MA 1990, p. 211.

    Google Scholar 

  7. Stampfer, MJ, Colditz, GA. Estrogen replacement and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prey Med 1991; 20: 47–63.

    Article  CAS  Google Scholar 

  8. Grady, D, Rubin, SM, Petitti, DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016.

    PubMed  CAS  Google Scholar 

  9. Utian WG, Schiff I. NAMS—Gallup survey on women’s knowledge, information sources and attitudes to menopause and hormone replacement therapy. Menopause 1994; 1: 39–48.

    Article  Google Scholar 

  10. Seeman E. Osteoporosis: trials and tribulations. Am J Med 1997; 18; 103: 74S - 87S.

    Article  Google Scholar 

  11. Eiken P, Kolthoff N, Nielsen SP. Effect of 10 years’ hormone replacement therapy on bone mineral content in postmenopausal women. Bone 1996; 5 (Suppl): 191S - 193S.

    Article  Google Scholar 

  12. Daly E, Roche M, Barlow D, Gray A, McPherson K, Vessey M. HRT: an analysis of benefits, risks and costs. Br Med Bull 1992; 48: 368–400.

    PubMed  CAS  Google Scholar 

  13. Van der Loos M, Paccaud F, Gutzwiller F, Chrzanowski R. Impact of hormonal prevention on fractures of the proximal femur in postmenopausal women: a simulation study. Soz Praventivmed 1988; 33: 162–166.

    Article  PubMed  Google Scholar 

  14. Speroff L, Lobo RA. Postmenopausal hormone therapy and the cardiovascular system. Heart Dis Stroke 1994; 3: 173–176.

    PubMed  CAS  Google Scholar 

  15. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987; 76: 465–479.

    Article  PubMed  CAS  Google Scholar 

  16. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer’s disease in women. Am J Epidemiol 1994; 140: 256–261.

    PubMed  CAS  Google Scholar 

  17. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer’s disease. Arch Intern Med 1996; 156: 2213–2217.

    Article  PubMed  CAS  Google Scholar 

  18. Brenner De, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer’ s disease: a population-based case-control study. Am J Epidemiol 1994; 140: 262–267.

    Google Scholar 

  19. Mortel KF, Meyers JS. Lack of postmenopausal estrogen replacement therapy and the risk of dementia. J Neuropsychiat Clin Neurosci 1996; 7: 334–337.

    Google Scholar 

  20. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of development of Alzheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology 1997; 48: 1517–1521.

    Article  PubMed  CAS  Google Scholar 

  21. Gould E, Wooley CS, Frankfurt M, McEwen BS. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J Neurosci 1990; 10: 1286–1291.

    PubMed  CAS  Google Scholar 

  22. Luine VN. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol 1985; 89: 484–490.

    Article  PubMed  CAS  Google Scholar 

  23. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994; 77: 817–827.

    Article  PubMed  CAS  Google Scholar 

  24. Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987; 156: 1332–1334.

    PubMed  CAS  Google Scholar 

  25. Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982; 144: 511–518.

    PubMed  CAS  Google Scholar 

  26. Jordan CV. Estrogen receptor antagonists. In: Adashi EY, Rock JA, Rosenwaks, eds. Reproductive endocrinology, surgery, and technology. Lippencott-Raven, Philadelphia, PA, 1996, p. 535.

    Google Scholar 

  27. Eighth Supplement to U.S.P. XXII. Easton, PA. Mack; 1990; 3256–3258.

    Google Scholar 

  28. Lobo RL, Nguyen HN, Eggena P, Brenner PF. Biologic effects of equilin sulfate in postmenopausal women. Fertil Steril 1988; 49: 234–238.

    PubMed  CAS  Google Scholar 

  29. Brosnihan KB, Weddle D, Anthony MS, Heise C, Li P, Ferrario CM. Effects of chronic hormone replacement on the renin-angiotensin system in cynomolgus monkeys. J Hypertens 1997; 15: 719–726.

    Article  PubMed  CAS  Google Scholar 

  30. Aylward M, Maddock J, Rees PL. Natural estrogen replacement therapy and blood clotting. Br Med J 1976; 1: 220–222.

    Article  PubMed  CAS  Google Scholar 

  31. Vanna TR. Effect of estrogen replacement on blood coagulation factors in postmenopausal women. Int J Gynaecol Obstet 1983; 21: 291–296.

    Article  Google Scholar 

  32. Perez-Gutthan. Hormone replacement therapy and risk of venous thromboembolism: population-based case controlled study. BMJ 1997; 314: 796–800.

    Article  Google Scholar 

  33. Wash Drug Lett. May 13, 1991: 6.

    Google Scholar 

  34. Bhavnani BR. Pharmacokinetics and pharmacodynamics of conjugated equine. estrogens: chemistry and metabolism. Proc Soc Exp Biol Med 1998; 217: 6–16.

    PubMed  CAS  Google Scholar 

  35. Yen SCC, Martin PL, Burnier AM, et al. Circulating estradiol, estrone, and gonadotropin levels following the administration of orally active 17 beta estradiol in post-menopausal women. J Clin Endocrinol Metab 1975; 40: 518–521.

    Article  PubMed  CAS  Google Scholar 

  36. Ryan KJ. Engel LL. Endocrinology 1953; 52: 287.

    Article  PubMed  CAS  Google Scholar 

  37. Lobo RA, Cassidenti DL. Pharmacokinetics of oral 17 beta estradiol. J Reprod Med 1992; 37: 77–84.

    PubMed  CAS  Google Scholar 

  38. Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990; 12: 171–197.

    Article  PubMed  CAS  Google Scholar 

  39. McEvoy GK, et al. eds. American Hospital Formulary Service. American Society of Hospital Pharmacists, Bethesda, MD, 1991.

    Google Scholar 

  40. Orme M, Back DJ, Ward S, Green S. The pharmacokinetics of ethinyl estradiol in the presence and absence of gestodene and desogestrel. Contraception 1991; 43: 305–316.

    Article  PubMed  CAS  Google Scholar 

  41. Mandel FP, Geoia Fl, Lu KH, Biologic effects of various doses of ethinyl estradiol in postmenopausal women. Obstet Gynecol 1982; 59: 673–679.

    PubMed  CAS  Google Scholar 

  42. Hammond CB, Maxon WS. Estrogen replacement therapy. Clin Obstet Gynecol 1986; 29:407–430. 43 Bewley S, Bewley TH. Drug dependence with estrogen replacement therapy. Lancet 1992; 339:290,291. 44. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J-A.Cloning of a novel receptor

    Google Scholar 

  43. expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925–5930.

    Article  Google Scholar 

  44. Mosselman S, Polman J, Dijkema R.ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392: 49–53.

    Article  PubMed  CAS  Google Scholar 

  45. Gambrel RD Jr. Use of progestogen therapy. Am J Obstet Gynecol 1987; 156: 1304–1313.

    Google Scholar 

  46. Persson I. Cancer risk in women receiving estrogen-progestin replacement therapy. Maturitas 1996; 23: S37 - S45.

    Article  PubMed  CAS  Google Scholar 

  47. Persson I, Thurfjell E, Bergstrom R, Holmberg L. Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer 1997; 72: 758–761.

    Article  PubMed  CAS  Google Scholar 

  48. von Schoultz B. HRT and breast cancer risk, what to advise? Eur J Obstet Gynecol Reprod Biol 1997; 71: 205–208.

    Article  PubMed  CAS  Google Scholar 

  49. Persson I, et al. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy: long-term follow-up of a Swedish cohort. Int J Cancer 1996; 67: 327–332.

    Article  PubMed  CAS  Google Scholar 

  50. Caldas GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589–1593.

    Article  Google Scholar 

  51. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic trials. Am J Obstet Gynecol 1993; 168: 1473–1480.

    PubMed  CAS  Google Scholar 

  52. Grodstein F, Stampfer MJ, Caldas GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769–1775.

    Article  PubMed  CAS  Google Scholar 

  53. Scarier C, Adami HO, Hoover R, Persson I. Cause-specific mortality in women receiving hormone therapy. Epidemiology 1997: 1: 59–65.

    Google Scholar 

  54. Peterson CM. Progestogens, progesterone antagonists, progesterone and androgens: Synthesis, classification, and uses. Clin Obstet Gynecol 1995; 38: 813–820.

    Article  Google Scholar 

  55. Moyer DL, de Lignieres B, Driguez P, Pez JP. Prevention of endometrial hyperplasia by progesterone during long term estradiol replacement: influence of bleeding pattern and secretory changes. Fertil Steril 1993; 59: 992–997.

    PubMed  CAS  Google Scholar 

  56. The Writing Group for the PEPI Trial. Effects of estrogen and estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI). JAMA 1995; 273: 199–208.

    Article  Google Scholar 

  57. Gillet JY, Andre G, Fauger B, Erny R, Buvat-Herbaut MA, et al. Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose. Multicenter study. Maturitas 1994; 19: 103–116.

    Article  PubMed  CAS  Google Scholar 

  58. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994; 62: 485–490.

    PubMed  CAS  Google Scholar 

  59. Casanas-Roux F, Nisolle M, Marbaix E, Smets M, Bassil S, Donnez J. Morphometric, immunohistological and three-dimensional evaluation of the endometrium of menopausal women treated by oestrogen and Crinone, a new slow-release vaginal progesterone. Hum Reprod 1996; 11: 357–363.

    Article  PubMed  CAS  Google Scholar 

  60. Jensen J, Rus BJ, Strin V, Nilas L, Christiansen C. Long term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol 1987; 156: 66–71.

    PubMed  CAS  Google Scholar 

  61. Shangold MM, Tomai TP, Cook JD, Jacobs SL, Zinaman MJ, Chin SY, Simon JA. Factors associated with withdrawal bleeding after administration of oral micronized progesterone in women with secondary amenorrhea. Fertil Steril 1991; 56: 1029–1033.

    Google Scholar 

  62. Whitehead MI, Hillard TC, Crook D. The role and use of progestogens. Obstet Gynecol 1990; 75: 559–576.

    Google Scholar 

  63. Woodruff JD, Pickar JH for The Menopause Study Group. Incidence of endometrial hyperplasia inpostmenopausal women taking conjugated estrogens with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994; 170: 1213.

    PubMed  CAS  Google Scholar 

  64. Ulrich LG, Barlow DH, Sturdee DW, Wells M, Campbell MJ, Nielsen B, Bragg AJ, Vessey MP. Quality of life and patient preference for sequential versus continuous combined HRT: the UK Kliofem multicenter study experience. UK Continuous Combined HRT Study Investigators. Int J Gynaecol Obstet 1997; 59: S11 - S17.

    PubMed  CAS  Google Scholar 

  65. Piegsa K, Calder A, Davis JA, McKay-Hart D, Wells M, Bryden F. Endometrial status in postmenopausal women on long-term continuous combined hormone replacement therapy (Kliofem). A comparative study of endometrial biopsy, outpatient hysteroscopy and transvaginal ultrasound. Eur J Obstet Gynecol Reprod Biol 1997; 72: 175–180.

    Article  PubMed  CAS  Google Scholar 

  66. Leather AT, Savvas IA, Studd JWW. Endometrial histology and bleeding patterns after eight years of continuous combined estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1991; 78: 1008–1010.

    PubMed  CAS  Google Scholar 

  67. Darj E, Nilsson S, Axelsson O, et al. Clinical and endometrial effects of estradiol and progesterone in postmenopausal women. Maturitas 1991; 13: 109–115.

    Article  PubMed  CAS  Google Scholar 

  68. Gambrell RD Jr. Progestogens in estrogen-replacement therapy. Clin Obstet Gynecol 1995; 38: 89–901.

    Article  Google Scholar 

  69. Casper RF, Chapdelaine A. Estrogen and interrupted progestin: a new concept for menopausal replacement therapy. Am J Obstet Gynecol 1993; 168: 1188–1196.

    PubMed  CAS  Google Scholar 

  70. Judd HL, Judd GE, Lucas WF, Yen S.C. Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J Clin Endo Metab 1974; 39: 1020.

    Article  CAS  Google Scholar 

  71. Vermilion A. The hormonal activity of the postmenopausal ovary. J Clin Endo Metab 1976; 42: 247–252.

    Article  Google Scholar 

  72. Furuhjelm M, Karlgren E, Carstrom K. The effect of estrogen therapy on somatic and psychical symptoms in postmenopausal women. Acta Obstet Gynecol Scand 1984; 63: 655–661.

    Article  PubMed  CAS  Google Scholar 

  73. Wallem K, Goy RW. Effects of estradiol benzoate, estrone, and proprionates of testosterone or dihydrotestosterone on sexual and related behaviors of ovariectomized rhesus monkeys. Horm Behav 1977; 9: 228–248.

    Article  Google Scholar 

  74. Michael RP, Zumpe D. Effects of androgen administration on sexual invitations by female rhesus monkeys. Anim Behav 1977; 25: 936–944.

    Article  PubMed  CAS  Google Scholar 

  75. Michael RP, Richter MC, Cain JA, et al. Artificial menstrual cycles, behavior and the role of androgens in female rhesus monkeys. Nature 1978; 175: 439–440.

    Article  Google Scholar 

  76. Michael RP, Zumpe D, Keverne EB, et al. Neuroendocrine factors in the control of primate behavior. Rec Prog Horm Res. 1972; 28: 665–706.

    PubMed  CAS  Google Scholar 

  77. Sherwin BB, Gelfand MM, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med 1985; 47: 339–351.

    PubMed  CAS  Google Scholar 

  78. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987; 49: 397–409.

    PubMed  CAS  Google Scholar 

  79. Sherwin BB, Gelfand MM. Differential symptoms response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 1985, 151: 153–160.

    PubMed  CAS  Google Scholar 

  80. Young R, Wilta B, Dabbs J, et al. Comparison of estrogen plus androgen and estrogen on libido and sexual satisfaction in recently oophorectomized women. North American Menopause Society Meeting, September 17–20, 1992.

    Google Scholar 

  81. Dow MTG, Hart DM. Hormonal treatments of sexual unresponsiveness in postmenopausal women. Br J Obstet Gynaecol 1983; 90: 361–366.

    Article  PubMed  CAS  Google Scholar 

  82. Sherwin BB, Gelfand MM. Sex steroids and affect in “the surgical menopause: a double blind, crossover study. Psychoneuroendocrinology I985; 10: 325–335.

    Google Scholar 

  83. Myers LS, Dixon J, Morrissette M, Carmichael M, Davidson JM. Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women. J Clin Endo Metab 1990; 70: 1124–1131.

    Article  CAS  Google Scholar 

  84. Notelovitz M, Watts N, Timmons MC, et al. Effects of estrogen plus low dose androgen versus estrogen alone on menopausal symptoms in oophorectomized-hysterectomized women. North American Menopausal Society Meeting, September 17–20, 1992.

    Google Scholar 

  85. Colvard DS, Erickson, EF, Meeting PE et al, Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci USA 1989; 86: 854–857.

    Article  PubMed  CAS  Google Scholar 

  86. Kasperk CH, Wergedeal JE, et al. Androgens directly stimulate proliferation of bone cells in vitro. Endocrinology 1989; 124: 1576, 1577.

    Google Scholar 

  87. Kasperk C, Fitzsimmons R, Strong D, et al. Studies of the mechanism by which androgens enhance mitogenesis and differentiation in bone cells. J Clin Endocrinol Metab 1990; 71: 1322–329.

    Article  PubMed  CAS  Google Scholar 

  88. Need AG, Horowitz M, Bridges A, Morris H, Nordic BE. Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic, postmenopausal women. Arch Int Med 1989; 149: 57–60.

    Article  CAS  Google Scholar 

  89. Raisz LG, Wiita B, Artis A, et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 1995; 81: 37–43.

    Article  Google Scholar 

  90. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the oestrogen-receptor gene in a man. N Engl J Med 1994; 331: 1056–1061.

    Article  PubMed  CAS  Google Scholar 

  91. Savvas M, Studd JWW, Fogelman I, et al. Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. Br Med J 1988; 297: 331–333.

    Article  CAS  Google Scholar 

  92. Savvas M, Studd JWW, Norman S, et al. Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in post-menopausal women who have previously received long-term oral oestrogens. Br J Obstet Gynaecol 1992; 757–760.

    Google Scholar 

  93. Davis SR, McCloud P, Strauss BJG, Burger HG. Testosterone enhances estradiol effects on postmenopausal bone density and sexuality. Maturitas 1995; 21: 227–236.

    Article  PubMed  CAS  Google Scholar 

  94. Garnet T, Studd, J, Watson N, Savvas M. The effects of plasma estradiol levels on increases in vertebral and femoral bone density following therapy with estradiol and estradiol with testosterone implants. Obstet Gynecol I 992; 79: 968–972.

    Google Scholar 

  95. Urman B, Pride SM, Ho Yeun BH. Elevated serum testosterone, hirsutism, and virilism associated with combined androgen-estrogen hormone replacement therapy. Obstet Gynecol. 1991; 77: 595–598.

    PubMed  CAS  Google Scholar 

  96. Hickok LR, Toomey C, Speroff L. A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women. Obstet Gynecol 1993; 82: 924–927.

    Google Scholar 

  97. Gelfand MM, Wiita B.Int J Fertil Menopausal Stud 1996; 41: 412–422.

    Google Scholar 

  98. Phillips E, Bauman C. Safety surveillance of esterified estrogens-methyltestosterone (Estratest and Estratest HS) replacement therapy in the United States. Clin Ther 1997; 19: 1070–1084.

    Article  PubMed  CAS  Google Scholar 

  99. Arjmandi BH, Alkel L, Hollis BW, Amin D, Stacewicz-Sapuntzakis M, Guo P, Kukreja SC. Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis.J Nutr 1996; 126: 161–167.

    CAS  Google Scholar 

  100. Jayo MJ, Anthony MS, Register TC, Rankin SE, Vest T, Clarkson TB. Dietary soy isoflavones and bone loss: a study in ovariectomized monkey. J Bone Miner Res 1996; 11: S228.

    Google Scholar 

  101. Anthony MS, Clarkson TB, Hughes CL, Morgan TM, Burke GL. Soybean isoflavones improve cardiovascular risk factors without affecting reproductive system of peripubertal rhesus monkeys. J Nutr 1996; 126: 43–50.

    PubMed  CAS  Google Scholar 

  102. Anthony MS, Burke GL, Hughes CL, Clarkson TB. Does soy supplementation improve coronary heart disease risk? Circulation 1995; 91: 925–929.

    Google Scholar 

  103. Anthony MS, Clarkson TB, Hughes CL. Plant and mammalian estrogen effects on plasma lipids of female monkeys. Circulation 1994; 90: 1235.

    Google Scholar 

  104. Williams JK, Honore EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994; 24: 1757–1761.

    Article  PubMed  CAS  Google Scholar 

  105. Messina MJ, Persky V, Setchell KDR, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994; 21: 113–131.

    Article  PubMed  CAS  Google Scholar 

  106. Lu LJ, Anderson KE, Grady JJ, Nagamani M. Effects of soya consumption for one month on steroid hormones in premenopausal women: implications for breast cancer risk reduction. Cancer Epidemiol Biomarkers Prey 1996; 5: 63–70.

    CAS  Google Scholar 

  107. Knight DC, Eden JA. A review of the clinical effects of phytoestrogens. Obstet Gynecol 1996; 87: 897–904.

    PubMed  CAS  Google Scholar 

  108. Orentreich N, Brind J, Rizer R, Vogelmen J. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentration throughout adulthood. J Clin Endocrinol Metab 1984; 59: 551–555.

    Article  PubMed  CAS  Google Scholar 

  109. Nestler JE, Barlascini CO, Clore JN, Blackard WG. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 1988; 66: 57–61.

    Article  PubMed  CAS  Google Scholar 

  110. Barrett-Conner E, Khaw KT. Absence of an inverse relation of dehydroepiandrosterone sulfate with cardiovascular mortality in postmenopausal women. N Engl J Med 1987; 317: 711–715.

    Google Scholar 

  111. Casson PR, Buster JE. DHEA Administration to humans: panacea or palaver? Sem Repro Endo 1995; 13: 247–256.

    Article  Google Scholar 

  112. Casson PR, Anderson RN, Herod HG. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol 1993; 169: 1536–1539.

    PubMed  CAS  Google Scholar 

  113. Khorran O, Vu L, Yen SCC. Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. J Gerontol 1997; 52A M1–7.

    Google Scholar 

  114. Buster JE, Casson PR, Stroaughn AB, et al. Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionnality studies. Am J Obstet Gynecol 1992; 166: 1163–1168.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. C. Matthew Peterson MD, FACOG
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lawrence C. Udoff MD,FACOG
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Endocrinology and Medicine, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA

    A. Wayne Meikle MD

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Peterson, C.M., Udoff, L.C. (1999). Primary and Secondary Hypogonadism in Women. In: Meikle, A.W. (eds) Hormone Replacement Therapy. Contemporary Endocrinology, vol 13. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-700-0_21

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-700-0_21

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-092-2

  • Online ISBN: 978-1-59259-700-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation